Profile image
Story Views

Last Hour:
Last 24 Hours:

Chronic Lymphocytic Leukemia Market 2016 Trend, Analysis and Overview

Friday, October 7, 2016 5:31
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Cancer that starts from the hematopoietic stem cells of the bone-marrow is referred to as leukemia. Leukemia can be chronic or acute depending on the maturity of the cells. In addition, based on the bone marrow cells from which the cancer starts, leukemia can be categorized as lymphocytic or myeloid. Hence, leukemia can be broadly classified into four types:
- Acute myeloid (or myelogenous) leukemia (AML)
- Chronic myeloid (or myelogenous) leukemia (CML)
- Acute lymphocytic (or lymphoblastic) leukemia (ALL)

Publisher’s analysts forecast the global CLL therapeutics market to grow at a CAGR of 19.16% during the period 2016-2020.

For more information about this report:         

Covered in this report 
The report covers the present scenario and the growth prospects of the global CLL therapeutics market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic drugs used to treat and prevent CLL. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography: 
- Americas

Publisher’s report, Global Chronic Lymphocytic Leukemia (CLL) Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. 

Key vendors 
- F. Hoffman-La Roche
- AbbVie 
- Teva Pharmaceuticals
- Gilead Sciences
- Novartis
- Johnson & Johnson


Request Sample Copy at         


Other prominent vendors 
- Altor BioScience
- Amgen
- Arno Therapeutics
- AstraZeneca 
- Bellicum Pharmaceuticals
- Biogen 
- BioLineRx 
- Boston Biomedical
- Celgene
- Emergent BioSolutions 
- Genzyme 
- iDD biotech 
- Immunomedics 
- Infinity Pharmaceuticals
- Innate Pharma 
- Karyopharm Therapeutics
- Ligand Pharmaceuticals 
- MedImmune
- Merck Sharp & Dohme
- Molecular Templates Inc. 
- MorphoSys 
- Ono Pharmaceutical
- Portola Pharmaceuticals
- Regeneron Pharmaceuticals 
- Sunesis Pharmaceuticals
- TG Therapeutics 
- TheraMAB 
- XEME Biopharma 
- Xencor 
- ZIOPHARM Oncology

Market driver 
- Special regulatory designations
- For a full, detailed list, view our report 

Market challenge 
- High cost of therapy
- For a full, detailed list, view our report 

Market trend 
- Rise in development of combination therapies
- For a full, detailed list, view our report 


Inquire for Report at         


Contact Us:

Call: +1-646-491-9876

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global


Top Alternative




Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.